These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27914135)

  • 1. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
    Lee JH; Kim HJ; Kim YH
    J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
    Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic treatment strategies for community-acquired pneumonia in adults.
    Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
    N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A; Shasha D; Paul M
    Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis.
    Nie W; Li B; Xiu Q
    J Antimicrob Chemother; 2014 Jun; 69(6):1441-6. PubMed ID: 24535276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
    Choi SH; Cesar A; Snow TAC; Saleem N; Arulkumaran N; Singer M
    Int J Antimicrob Agents; 2023 Sep; 62(3):106905. PubMed ID: 37385561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of First-Line and Alternative Antibiotic Regimens in Hospitalized Patients With Nonsevere Community-Acquired Pneumonia: A Multicenter Retrospective Cohort Study.
    Bai AD; Srivastava S; Wong BKC; Digby GC; Razak F; Verma AA
    Chest; 2024 Jan; 165(1):68-78. PubMed ID: 37574164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.
    Wilson BZ; Anzueto A; Restrepo MI; Pugh MJ; Mortensen EM
    Crit Care Med; 2012 Aug; 40(8):2310-4. PubMed ID: 22622401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
    Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG
    JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
    Kılıç Soylar Ö; Kılınç O; Ellidokuz H
    Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis.
    Vardakas KZ; Trigkidis KK; Falagas ME
    Clin Microbiol Infect; 2017 Apr; 23(4):234-241. PubMed ID: 27965070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?
    Ruhe J; Mildvan D
    Infect Dis Clin North Am; 2013 Mar; 27(1):115-32. PubMed ID: 23398869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.
    Vardakas KZ; Siempos II; Grammatikos A; Athanassa Z; Korbila IP; Falagas ME
    CMAJ; 2008 Dec; 179(12):1269-77. PubMed ID: 19047608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dilemma of monotherapy or combination therapy in community-acquired pneumonia.
    Vardakas KZ; Trigkidis KK; Apiranthiti KN; Falagas ME
    Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29027205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
    Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
    J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy.
    Okumura J; Shindo Y; Takahashi K; Sano M; Sugino Y; Yagi T; Taniguchi H; Saka H; Matsui S; Hasegawa Y;
    Respirology; 2018 May; 23(5):526-534. PubMed ID: 29239493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.